Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine von Grob, J.-J, Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller Jr., W. H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

kostenfrei
kostenfrei
kostenfrei